540 F.Supp.3d 141
D. Mass.2021Background
- Azurity (plaintiff) sued Edge (defendant), alleging Edge, an outsourcing compounding facility, marketed a vancomycin hydrochloride product on its website as FDA-compliant and thus made false advertising claims under the Lanham Act and Mass. Gen. Laws ch. 93A.
- Azurity alleges Edge’s product is "essentially a copy" of Azurity’s approved product and that Edge’s advertising misrepresents compliance with the FDCA; FDA has not found Edge in violation as to that product.
- Edge moved to dismiss under Fed. R. Civ. P. 12(b)(6); Azurity also sought a preliminary injunction (later denied as moot after dismissal).
- The court noted that enforcement and interpretation of the FDCA and related FDA policies are committed to the FDA, and private Lanham Act suits cannot be used to litigate underlying FDCA violations when the FDA has not determined a violation.
- The district court dismissed the Lanham Act claim as precluded because litigating it would require resolving complex FDCA questions committed to the FDA; the 93A claim was dismissed as derivative of the Lanham Act theory.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Azurity may pursue a Lanham Act false-advertising claim that requires determining an FDCA violation (e.g., whether Edge’s product is “essentially a copy” and FDA-noncompliant) | Azurity: Edge’s website falsely claims FDA compliance; court can adjudicate Lanham Act claim | Edge: Adjudication would require resolving FDCA/regulatory issues reserved to the FDA; Lanham Act cannot be used to enforce FDCA | Court: Dismissed Lanham Act claim — suit would require resolving FDCA issues entrusted to FDA, so precluded |
| Whether Azurity’s Mass. Gen. Laws ch. 93A claim survives independent of the Lanham Act claim | Azurity: 93A claim based on same factual misrepresentations, separate consumer protection remedy | Edge: 93A claim depends on the same alleged FDCA noncompliance and thus fails with Lanham claim | Court: Dismissed 93A claim as it rests on same precluded allegations |
Key Cases Cited
- Ashcroft v. Iqbal, 556 U.S. 662 (2009) (pleading standard — plausibility required)
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007) (pleading standard foundational precedent)
- Watterson v. Page, 987 F.2d 1 (1st Cir. 1993) (accept factual allegations and draw inferences on Rule 12(b)(6))
- Cashmere & Camel Hair Mfrs. Inst. v. Saks Fifth Ave., 284 F.3d 302 (1st Cir. 2002) (elements of Lanham Act false-advertising claim)
- POM Wonderful LLC v. Coca-Cola Co., 573 U.S. 102 (2014) (FDCA enforcement generally committed to FDA)
- PhotoMedex, Inc. v. Irwin, 601 F.3d 919 (9th Cir. 2010) (Lanham Act claim precluded where it would require litigating FDCA violations absent FDA determination)
- Sandoz Pharm. Corp. v. Richardson-Vicks, Inc., 902 F.2d 222 (3d Cir. 1990) (courts should not use Lanham Act to indirectly create FDCA private rights)
- JHP Pharm., Ltd. Liab. Co. v. Hospira, Inc., 52 F. Supp. 3d 992 (C.D. Cal. 2014) (determination of whether a drug may be lawfully marketed implicates FDA authority)
- Reed v. Zipcar, Inc., 883 F. Supp. 2d 329 (D. Mass. 2012) (Chapter 93A requires independent arguments to survive when premised on other legal violations)